Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.41 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350197 | 1.00 | NOD1 (0.41) | NOD1GGT1C3AR1TLR2MEN1 | |
| Hydrochloric Acid SCHEMBL26096762 | 0.98 | NOD1 (0.40) | NOD1GGT1C3AR1TLR2MEN1 | |
| SCHEMBL6429710 | 0.92 | NOD1 (0.49) | NOD1GGT1C3AR1TLR2FOLH1 | |
| SCHEMBL1343491 | 0.92 | NOD1 (0.49) | NOD1GGT1C3AR1TLR2FOLH1 | |
| Benzene SCHEMBL28171540 | 0.92 | C3AR1 (0.38) | NOD1GGT1C3AR1TLR2ITGB3 | |
| SCHEMBL5983126 | 0.91 | NOD1 (0.51) | NOD1TLR2ITGB3ITGA2BFOLH1 | |
| SCHEMBL5983133 | 0.91 | NOD1 (0.51) | NOD1TLR2ITGB3ITGA2BFOLH1 | |
| SCHEMBL25334014 | 0.90 | NOD1 (0.53) | NOD1TLR2FOLH1DPP7FNTA | |
| SCHEMBL7029222 | 0.90 | NOD1 (0.53) | NOD1TLR2FOLH1DPP7FNTA | |
| SCHEMBL8664762 | 0.90 | NOD1 (0.53) | NOD1TLR2FOLH1DPP7FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| US-20250325551-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | UNIV LOUISIANA STATE (US) | 2025-10-23 | — | — | US | claimed |
| US-12280058-B2 | Gasotransmitter metabolites and Alzheimer's disease | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-04-22 | — | — | US | claimed |
| CN-119837782-A | Hair care composition based on disulfide bond repair, cosmetic and application | 广州澳谷化妆品制造有限公司 | 2025-04-18 | — | — | CN | claimed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| CN-115501127-B | Anti-inflammatory and allergy-relieving composition and daily chemical product | 梅晔生物医药股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20210285938-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-09-16 | — | — | US | claimed |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL Biomedica PLC c/o Finance Division University College of London (GB) | 2009-03-12 | — | — | US | claimed |
| EP-0922454-B1 | Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor | UNIV TEXAS (US) | 2005-11-16 | — | — | EP | claimed |
| EP-0592557-B1 | NITRIC OXIDE SYNTHESIS INHIBITORS FOR POTENTIATING THE ACTION OF PRESSOR AGENTS IN CERTAIN HYPOTENSIVE PATIENTS | UNIV TEXAS (US) | 2000-02-02 | — | — | EP | claimed |
| EP-0922454-A2 | Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor | Board of Regents, The University of Texas System (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0597831-B1 | ARGININE ANTAGONISTS FOR INHIBITION OF SYSTEMIC HYPOTENSION ASSOCIATED WITH NITRIC OXIDE PRODUCTION OR ENDOTHELIAL DERIVED RELAXING FACTOR | UNIV TEXAS (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0597831-A1 | ARGININE ANTAGONISTS FOR INHIBITION OF SYSTEMIC HYPOTENSION ASSOCIATED WITH NITRIC OXIDE PRODUCTION OR ENDOTHELIAL DERIVED RELAXING FACTOR | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-05-25 | — | — | EP | claimed |
| WO-1991004024-A1 | ARGININE ANTAGONISTS FOR INHIBITION OF SYSTEMIC HYPOTENSION ASSOCIATED WITH NITRIC OXIDE PRODUCTION OR ENDOTHELIAL DERIVED RELAXING FACTOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-04-04 | — | — | WO | claimed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250325551-A1 | GASOTRANSMITTER METABOLITES AND ALZHEIMER'S DISEASE | UNIV LOUISIANA STATE (US) | 2025-10-23 | — | — | US | disclosed |
| US-5110798-A | Immunomodulators for bone marrow transplants | CO PHARMA CORPORATION S.R.L. (IT) | 1992-05-05 | — | — | US | disclosed |
| EP-0346460-A1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION. | CO PHARMA CORP SRL (IT) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989005818-A1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION | CO PHARMA CORPORATION S.R.L. (IT) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | NOD1 2132/4885GGT1 386/4885C3AR1 4128/4885 |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | DDAH1, DOHH, IMPDH1 | NOD1 2690/4885GGT1 28/4885C3AR1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.